Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381939 | 0.82 | PKM (0.48) | PKMATMSCD5TSHRALOX15 | |
| SCHEMBL3325807 | 0.80 | GPR119 (0.41) | PKMSCD5ACACBGPR119KMT2A | |
| SCHEMBL3325803 | 0.80 | PKM (0.41) | PKMSCD5ACACBKMT2ANAMPT | |
| SCHEMBL11963328 | 0.76 | PKM (0.44) | PKMATMTSHRALOX15GPR119 | |
| SCHEMBL23089691 | 0.74 | ATM (0.47) | PKMATMTSHRALOX15GPR119 | |
| SCHEMBL20266353 | 0.74 | TSHR (0.47) | PKMATMTSHRALOX15KMT2A | |
| SCHEMBL29736610 | 0.74 | ATM (0.47) | PKMATMTSHRALOX15GPR119 | |
| SCHEMBL29556016 | 0.74 | TSHR (0.47) | PKMATMTSHRALOX15KMT2A | |
| SCHEMBL31382726 | 0.74 | TSHR (0.51) | PKMATMTSHRALOX15GPR119 | |
| SCHEMBL31382005 | 0.74 | GPR119 (0.53) | PKMATMTSHRALOX15GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | PKM 3716/4885ATM 929/4885SCD5 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.